Answers are grounded in this paper and cite their sources.
Identifies CD30 as a crucial cytokine receptor for diagnosing non-Hodgkin's lymphomas, particularly ALCL, suggesting its potential in immunotherapy.
THE INITIAL description of the Ki-l monoclonal antibody (MoAb) in 1982,' there has been an overwhelming flood of information concerning the Hodgkm's disease @)associated molecule CD30. In a diagnostic point of view, the Ki-l antibody enabled in 1985' the identification of a new category of non-Hodgkn's lymphomas designated as Ki"D30 anaplastic large cell lymphoma (ALCL).'
No takes yet. Share an insight, caveat, or question.
Falini et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: